

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
FOR
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Page
Report of the Trustees	1 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Cash Flow Statement	8
Notes to the Cash Flow Statement	9
Notes to the Financial Statements	10 to 15
Detailed Statement of Financial Activities	16 to 17

BRITISH NUCLEAR MEDICINE SOCIETY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to raising the profile of nuclear medicine and to promote the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

Significant activities

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

BRITISH NUCLEAR MEDICINE SOCIETY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024

OBJECTIVES AND ACTIVITIES

Our committees

Professional Standards Committee

The Professional Standards Committee advises the Officers and Council of BNMS on the development and implementation on professional standards and audit. They develop, promote, publicise and review guidelines for the delivery of nuclear medicine services and procedures and are also responsible for developing patient information in nuclear medicine.

Scientific and Education Committee

The British Nuclear Medicine Society (BNMS) established the combined Scientific Committee and Education Committee in 2016.

The mandate of the Scientific and Education Committee is to develop an education and scientific programme, nominate invited speakers and the chairs of sessions.

The remit of this committee is to provide resources and encourage the provision of education and training to support Continuing Professional Development/Continuous Medical Education and work towards revalidation. The Education Committee is Multidisciplinary, consisting of Nuclear Medicine Physicians, Clinical Practitioners, Physicists, Nurses and Radiopharmacists.

Research & Innovation Committee

Research & Innovation Committee (RIC) reports to BNMS council and governs BNMS Research Champions network and links to the MRT Research Committee.

The purpose of the RIC is to provide integrated clinical, scientific and operational leadership and management/oversight of delivery of the BNMS Research Strategy.

The roles of the Research & Innovation Committee are to develop and deliver BNMS Research Strategy with aims:

1. To enhance radionuclide research delivery in the United Kingdom leading to service improvement and better care of patients. To accomplish this the BNMS will outline research priority areas highlighting current unmet needs. It will investigate through research sessions and workshops on-line and at face-to-face meetings on how best its multi professional membership can develop projects and achieve funding from the appropriate bodies. The BNMS will facilitate research networks through the BNMS website and offer peer support and review through face-to-face meetings at the BNMS conferences. It will endeavour to contribute to and work with the professional bodies involved in research, the UK Colleges, the charities, and the national and international Nuclear Medicine societies. It will foster links with research partners including the UK PET Network the CRUK Radiation Network, RadNet, the National Cancer Imaging Translational Accelerator (NCITA) and Industry Academic partnership via Industry forum held 2-3 times a year.

2. To build up an evidence base for new radionuclide molecular diagnostic and therapeutic procedures. The BNMS research network group is developing a data base of current research in the UK and a data base of available research funding. It is also developing a data base to ethically collect data from ongoing research studies.

UK MRT Consortium

The UK molecular radiotherapy consortium is a group comprised of both healthcare professionals and patient advocates who are directly and passionately associated in delivering and caring for patients undergoing molecular radiotherapy based treatments.

The UK MRT Consortium are the first organisation to serve current and future patients who may find the need to receive such types of treatment to help maintain and sustain both quality and duration of life.

By bringing members and fellows of both the British Nuclear Medicine Society and the Royal College of Radiologists together along with patient advocates and nationally recognised charities, we will endeavour to ensure that all parts of the United Kingdom will have equitable access to current and future therapies, raise public awareness of such treatments, design and encourage activity in nationally recognised molecular radiotherapy trials.

Trainee Committee

Aims of BNMS Medical Trainee Committee

Increase awareness of diagnostic and therapeutic Nuclear Medicine amongst doctors-in-training and medical students.
Provide educational content for doctors-in-training and medical students to aid their understanding of working in Nuclear Medicine and the training pathways.
Provide opportunities for doctors-in -training and medical students to engage with the BNMS and improve their application for the specialties/training numbers.

Radiographers Technologists and Nurses

The BNMS Radiographers, Technologists & Nurses' Committee:-

- Represents Radiographers, Technologists & Nurses on the BNMS Council
- Organises sessions at the BNMS Meetings
- Provides advice and opinion on issues affecting all 3 groups

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

OBJECTIVES AND ACTIVITIES

Objectives

- To unite Radiographers, Technologists & Nurses working in Nuclear Medicine into one professional association.
- To encourage professional development and education of these 3 groups by:
 - * Co-operating with existing organisations providing education and training
 - * Supporting and endorsing existing organisations providing education and training.
- To represent the group within the British Nuclear Medicine Society, including participation in organisation of sessions at the Spring and Autumn BNMS meetings.

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Belfast £	Autumn Norwich £	Online Educational £	Total £
Income				
Commercial exhibition income	202,375	18,336	5,008	225,718
Annual conference delegate registration fees	112,809	13,840	8,366	135,015
	315,184	32,177	13,374	360,734
Less: Scientific meeting expenses	261,309	21,523	12,966	295,799
Surplus	53,874	10,653	408	64,935

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FINANCIAL REVIEW

Reserves policy

The trustees aim to maintain general reserve levels at the equivalent of at least 18 months expenditure. The unrestricted fund balance (excluding designated funds) at the year end of £466,821 is above this level and continues to be carefully monitored by the trustees.

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians
11 St Andrews Place
Regents Park
London
NW1 4LE

BRITISH NUCLEAR MEDICINE SOCIETY

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

Trustees

Who are also directors

Mrs J Croasdale

Dr R Graham (resigned 13 May 2024)

Dr S Redman (resigned 20 May 2025)

Mr C S Kalirai

Mrs S Dizdarevic (appointed 13 May 2024)

Radiopharmacist

Radiologist

Radiologist

Clinical Scientist

Professor

Independent Examiner

E R Grove & Co Limited

Grove House

Coombs Wood Court

Steel Park Road

Halesowen

West Midlands

B62 8BF

Approved by order of the board of trustees on 8 May 2025 and signed on its behalf by:

Mr C S Kalirai - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited
Grove House
Coombs Wood Court
Steel Park Road
Halesowen
West Midlands
B62 8BF

8 May 2025

BRITISH NUCLEAR MEDICINE SOCIETY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	Unrestricted fund £	Restricted fund £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	-	-	-	4,400
Other trading activities	3	441,142	-	441,142	412,766
Investment income	4	9,414	207	9,621	5,933
Other income		<u>75,454</u>	<u>-</u>	<u>75,454</u>	<u>90,564</u>
Total		<u>526,010</u>	<u>207</u>	<u>526,217</u>	<u>513,663</u>
EXPENDITURE ON					
Raising funds	5	<u>542,381</u>	<u>-</u>	<u>542,381</u>	<u>422,297</u>
NET INCOME/(EXPENDITURE)		(16,371)	207	(16,164)	91,366
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>465,512</u></u>	<u><u>14,480</u></u>	<u><u>479,992</u></u>	<u><u>496,156</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

BALANCE SHEET 31 DECEMBER 2024

	Notes	Unrestricted fund £	Restricted fund £	2024 Total funds £	2023 Total funds £
FIXED ASSETS					
Tangible assets	11	1,644	-	1,644	2,415
CURRENT ASSETS					
Debtors	12	243,023	-	243,023	168,525
Cash at bank		<u>405,521</u>	<u>14,480</u>	<u>420,001</u>	<u>433,145</u>
		648,544	14,480	663,024	601,670
CREDITORS					
Amounts falling due within one year	13	(184,676)	-	(184,676)	(107,929)
NET CURRENT ASSETS		<u>463,868</u>	<u>14,480</u>	<u>478,348</u>	<u>493,741</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		465,512	14,480	479,992	496,156
NET ASSETS		<u>465,512</u>	<u>14,480</u>	<u>479,992</u>	<u>496,156</u>
FUNDS	14				
Unrestricted funds				465,512	481,883
Restricted funds				<u>14,480</u>	<u>14,273</u>
TOTAL FUNDS				<u>479,992</u>	<u>496,156</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 8 May 2025 and were signed on its behalf by:

Mr C S Kalirai - Trustee

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	2024 £	2023 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(22,766)</u>	<u>80,923</u>
Net cash (used in)/provided by operating activities		<u>(22,766)</u>	<u>80,923</u>
 Cash flows from investing activities			
Purchase of tangible fixed assets		1	(433)
Interest received		<u>9,621</u>	<u>5,933</u>
Net cash provided by investing activities		<u>9,622</u>	<u>5,500</u>
		<hr/>	<hr/>
Change in cash and cash equivalents in the reporting period		(13,144)	86,423
Cash and cash equivalents at the beginning of the reporting period		<u>433,145</u>	<u>346,722</u>
 Cash and cash equivalents at the end of the reporting period		<u><u>420,001</u></u>	<u><u>433,145</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2024 £	2023 £
Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)	(16,164)	91,366
Adjustments for:		
Depreciation charges	770	1,147
Interest received	(9,621)	(5,933)
(Increase)/decrease in debtors	(74,498)	20,748
Increase/(decrease) in creditors	<u>76,747</u>	<u>(26,405)</u>
Net cash (used in)/provided by operations	<u><u>(22,766)</u></u>	<u><u>80,923</u></u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.24 £	Cash flow £	At 31.12.24 £
Net cash			
Cash at bank	<u>433,145</u>	<u>(13,144)</u>	<u>420,001</u>
	<u>433,145</u>	<u>(13,144)</u>	<u>420,001</u>
Total	<u><u>433,145</u></u>	<u><u>(13,144)</u></u>	<u><u>420,001</u></u>

The notes form part of these financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available of use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

2. DONATIONS AND LEGACIES

	2024	2023
	£	£
Donations	<u>-</u>	<u>4,400</u>

3. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Commercial exhibition income	225,718	187,021
Annual conference delegate registration fees	135,015	148,480
Commission received	1,288	4,124
Royalties received	75,835	71,861
Other project income	<u>3,286</u>	<u>1,280</u>
	<u>441,142</u>	<u>412,766</u>

4. INVESTMENT INCOME

	2024	2023
	£	£
Deposit account interest	<u>9,621</u>	<u>5,933</u>

5. RAISING FUNDS

Raising donations and legacies

	2024	2023
	£	£
Support costs	<u>121,255</u>	<u>141,820</u>

Other trading activities

	2024	2023
	£	£
Purchases	300,138	239,557
Awards and prizes	2,748	1,432
Journal subscriptions	74,029	39,488
Support costs	<u>44,211</u>	<u>-</u>
	<u>421,126</u>	<u>280,477</u>

Aggregate amounts	<u>542,381</u>	<u>422,297</u>
-------------------	----------------	----------------

6. SUPPORT COSTS

	Management	Finance	Other	Governance	Totals
	£	£	£	costs £	£
Raising donations and legacies	121,015	-	-	240	121,255
Other trading activities	<u>32,944</u>	<u>3,578</u>	<u>770</u>	<u>6,919</u>	<u>44,211</u>
	<u>153,959</u>	<u>3,578</u>	<u>770</u>	<u>7,159</u>	<u>165,466</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

7. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Other assurance services	5,360	3,831
Depreciation - owned assets	<u>771</u>	<u>1,146</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

Trustees' expenses

Payments totalling £4,761 (2022: £1,645) were made to trustees to reimburse travel costs to conferences and council meetings.

9. STAFF COSTS

	2024	2023
	£	£
Wages and salaries	117,999	86,558
Other pension costs	<u>3,016</u>	<u>3,079</u>
	<u>121,015</u>	<u>89,637</u>

The average monthly number of employees during the year was as follows:

	2024	2023
	<u>3</u>	<u>3</u>
Administrative		

No employees received emoluments in excess of £60,000.

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	4,400	-	4,400
Other trading activities	412,849	(83)	412,766
Investment income	5,768	165	5,933
Other income	<u>90,564</u>	<u>-</u>	<u>90,564</u>
Total	<u>513,581</u>	<u>82</u>	<u>513,663</u>
EXPENDITURE ON			
Raising funds	<u>422,080</u>	<u>217</u>	<u>422,297</u>
NET INCOME/(EXPENDITURE)	91,501	(135)	91,366
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>390,382</u>	<u>14,408</u>	<u>404,790</u>
TOTAL FUNDS CARRIED FORWARD	481,883	14,273	496,156

=====

=====

=====

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

11. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2024 and 31 December 2024	<u>905</u>	<u>30,534</u>	<u>31,439</u>
DEPRECIATION			
At 1 January 2024	718	28,306	29,024
Charge for year	<u>28</u>	<u>743</u>	<u>771</u>
At 31 December 2024	<u>746</u>	<u>29,049</u>	<u>29,795</u>
NET BOOK VALUE			
At 31 December 2024	<u>159</u>	<u>1,485</u>	<u>1,644</u>
At 31 December 2023	<u>187</u>	<u>2,228</u>	<u>2,415</u>

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024 £	2023 £
Trade debtors	76,022	49,542
Other debtors	73,955	39,132
VAT	10,541	-
Prepayments and accrued income	<u>82,505</u>	<u>79,851</u>
	<u>243,023</u>	<u>168,525</u>

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024 £	2023 £
Trade creditors	59,558	4,160
Social security and other taxes	2,539	1,959
VAT	-	13,989
Other creditors	116,877	82,440
Accrued expenses	<u>5,702</u>	<u>5,381</u>
	<u>184,676</u>	<u>107,929</u>

14. MOVEMENT IN FUNDS

	At 1.1.24 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	481,883	(16,371)	465,512
Restricted funds			
Ross Breen Fund	<u>14,273</u>	<u>207</u>	<u>14,480</u>
TOTAL FUNDS	<u>496,156</u>	<u>(16,164)</u>	<u>479,992</u>

BRITISH NUCLEAR MEDICINE SOCIETY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024**

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	526,010	(542,381)	(16,371)
Restricted funds			
Ross Breen Fund	207	-	207
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>526,217</u>	<u>(542,381)</u>	<u>(16,164)</u>

Comparatives for movement in funds

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	390,382	91,501	481,883
Restricted funds			
Ross Breen Fund	14,408	(135)	14,273
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>404,790</u>	<u>91,366</u>	<u>496,156</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	513,581	(422,080)	91,501
Restricted funds			
Ross Breen Fund	82	(217)	(135)
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>513,663</u>	<u>(422,297)</u>	<u>91,366</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.23 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	390,382	75,130	465,512
Restricted funds			
Ross Breen Fund	14,408	72	14,480
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>404,790</u>	<u>75,202</u>	<u>479,992</u>

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2024

14. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	1,039,591	(964,461)	75,130
Restricted funds			
Ross Breen Fund	289	(217)	72
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>1,039,880</u>	<u>(964,678)</u>	<u>75,202</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2024.

BRITISH NUCLEAR MEDICINE SOCIETY

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	2024 £	2023 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	-	4,400
Other trading activities		
Commercial exhibition income	225,718	187,021
Annual conference delegate registration fees	135,015	148,480
Commission received	1,288	4,124
Royalties received	75,835	71,861
Other project income	<u>3,286</u>	<u>1,280</u>
	441,142	412,766
Investment income		
Deposit account interest	9,621	5,933
Other income		
Members subscriptions	<u>75,454</u>	<u>90,564</u>
Total incoming resources	526,217	513,663
EXPENDITURE		
Other trading activities		
Scientific meeting expenses	295,799	238,607
Other project expenses	4,339	950
Awards and prizes	2,748	1,432
Journal subscriptions	<u>74,029</u>	<u>39,488</u>
	376,915	280,477
Support costs		
Management		
Wages and social security	117,999	86,558
Pensions	3,016	3,079
Rent	1,312	1,280
Insurance	1,112	1,033
Subscriptions	2,080	678
Telephone	681	709
Postage and stationery	658	867
General meeting and travelling expenses	13,907	19,711
Sundries	247	355
Computer costs	<u>12,947</u>	<u>19,398</u>
	153,959	133,668
Finance		
Bank charges	1,646	1,681
Card charges	446	-
Direct debit processing costs	<u>1,486</u>	<u>1,253</u>
	3,578	2,934
Other		
Fixtures and fittings	28	33
Carried forward	28	33

This page does not form part of the statutory financial statements

BRITISH NUCLEAR MEDICINE SOCIETY

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	2024 £	2023 £
Other		
Brought forward	28	33
Computer equipment	<u>742</u>	<u>1,114</u>
	770	1,147
Governance costs		
Auditors' remuneration for non audit work	5,360	3,831
Payroll costs	240	240
Professional fees	250	-
Bookkeeping	<u>1,309</u>	<u>-</u>
	<u>7,159</u>	<u>4,071</u>
Total resources expended	<u>542,381</u>	<u>422,297</u>
Net (expenditure)/income	<u><u>(16,164)</u></u>	<u><u>91,366</u></u>

This page does not form part of the statutory financial statements